hsa-miR-9-5p Down-Regulates HK2 and Confers Radiosensitivity to Nasopharyngeal Carcinoma

Area of Science:

• Oncology
• Molecular Biology
• Radiotherapy Research

Background:

• Nasopharyngeal carcinoma (NPC) presents challenges in radiotherapy.
• Understanding molecular mechanisms of radioresistance is crucial for improving NPC treatment.
• Hexokinase 2 (HK2) is implicated in cancer cell metabolism and survival.

Purpose of the Study:

• To investigate the role of hsa-miR-9-5p in regulating radiotherapy sensitivity in NPC.
• To determine if hsa-miR-9-5p targets hexokinase 2 (HK2) in NPC cells.
• To evaluate the impact of hsa-miR-9-5p on NPC cell proliferation, apoptosis, and tumor growth in response to radiotherapy.

Main Methods:

• Quantitative real-time PCR (qRT-PCR) to measure hsa-miR-9-5p and HK2 levels.
• Dual luciferase reporter gene assay to confirm hsa-miR-9-5p targeting of HK2.
• Cell viability (CCK-8), apoptosis (flow cytometry), and colony formation assays to assess cellular response to irradiation.
• Western blotting to evaluate HK2 protein expression.
• (18F)-Flourodeoxyglucose uptake and in vivo tumor growth studies to assess treatment efficacy.

Main Results:

• hsa-miR-9-5p was found to directly target and inhibit HK2 expression.
• Overexpression of hsa-miR-9-5p led to decreased cell proliferation and increased apoptosis in NPC cells following radiation therapy.
• In vivo studies demonstrated that hsa-miR-9-5p significantly inhibited tumor growth in combination with radiation therapy.

Conclusions:

• hsa-miR-9-5p acts as a tumor suppressor in NPC by targeting HK2.
• hsa-miR-9-5p enhances the radiosensitivity of nasopharyngeal carcinoma.
• Targeting hsa-miR-9-5p represents a potential therapeutic strategy to improve radiotherapy outcomes in NPC patients.